255 related articles for article (PubMed ID: 15610657)
41. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
42. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
43. The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia.
Banerji V; Johnston JB; Seftel MD
Transfus Apher Sci; 2007 Aug; 37(1):57-62. PubMed ID: 17919979
[TBL] [Abstract][Full Text] [Related]
44. Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment.
Hallek M; Bergmann M; Emmerich B
Onkologie; 2004 Feb; 27(1):97-104. PubMed ID: 15007256
[TBL] [Abstract][Full Text] [Related]
45. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.
Nastoupil LJ; Sinha R; Flowers CR
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1089-108. PubMed ID: 23919536
[TBL] [Abstract][Full Text] [Related]
46. Modern concepts in the treatment of chronic lymphocytic leukemia.
Smolej L
Hematology; 2009 Oct; 14(5):249-54. PubMed ID: 19843378
[TBL] [Abstract][Full Text] [Related]
47. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Byrd JC; Rai KR; Sausville EA; Grever MR
Semin Oncol; 1998 Feb; 25(1):65-74. PubMed ID: 9482528
[TBL] [Abstract][Full Text] [Related]
48. [Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia].
Guièze R; Ysebaert L; de Guibert S; Dhédin N; Bay JO; Troussard X; Tournilhac O
Bull Cancer; 2012 Dec; 99(12):1123-32. PubMed ID: 23249977
[TBL] [Abstract][Full Text] [Related]
49. Chronic lymphocytic leukemia (CLL): first-line treatment.
Hallek M;
Hematology Am Soc Hematol Educ Program; 2005; ():285-91. PubMed ID: 16304393
[TBL] [Abstract][Full Text] [Related]
50. Chronic lymphocytic leukemia: new concepts and emerging therapies.
Ahmadi T; Maniar T; Schuster S; Stadtmauer E
Curr Treat Options Oncol; 2009 Apr; 10(1-2):16-32. PubMed ID: 19169831
[TBL] [Abstract][Full Text] [Related]
51. Chronic lymphocytic leukemia . Clinical oral poster session.
Keating MJ
Hematol Cell Ther; 2000 Jun; 42(1):35-9. PubMed ID: 11036949
[No Abstract] [Full Text] [Related]
52. Chronic lymphocytic leukemia: diagnosis and treatment.
Yee KW; O'Brien SM
Mayo Clin Proc; 2006 Aug; 81(8):1105-29. PubMed ID: 16901035
[TBL] [Abstract][Full Text] [Related]
53. Improving treatment for patients with chronic lymphocytic leukemia.
Shanafelt TD
Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
[TBL] [Abstract][Full Text] [Related]
54. How to improve the treatment outcome in chronic lymphocytic leukemia?
Robak T
Leuk Res; 2010 Mar; 34(3):272-5. PubMed ID: 19682742
[No Abstract] [Full Text] [Related]
55. Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?
Varghese AM; Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2010 Jan; 5(1):35-44. PubMed ID: 20425395
[TBL] [Abstract][Full Text] [Related]
56. Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices.
Tadmor T; Polliack A
Blood Rev; 2012 Jan; 26(1):15-23. PubMed ID: 21955980
[TBL] [Abstract][Full Text] [Related]
57. Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.
Nabhan C; Dalal N; Mehta J; Kay NE
Leuk Lymphoma; 2011 Mar; 52(3):374-86. PubMed ID: 21323519
[TBL] [Abstract][Full Text] [Related]
58. Critical factors in new therapeutic approaches in chronic lymphocytic leukaemia (CLL).
Rozman C; Montserrat E
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):453-5. PubMed ID: 3065742
[TBL] [Abstract][Full Text] [Related]
59. Lenalidomide in CLL: what is the optimal dose?
Wendtner CM
Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
[No Abstract] [Full Text] [Related]
60. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia.
Binet JL; Mentz F; Leblond V; Merle-Beral H
Leukemia; 1995 Dec; 9(12):2159-61. PubMed ID: 8609738
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
